Diagnostic Workup for Transient Ischemic Attack in Patients < 40 Years

Immediate Core Evaluation

• Urgent brain imaging with non‑contrast CT or, preferably, MRI is required to rule out intracranial hemorrhage and to identify acute ischemia; MRI detects small ischemic lesions that CT may miss. 1, 2, 3
• Comprehensive vascular imaging of both extracranial and intracranial arteries—using carotid Doppler ultrasound combined with CTA or MRA—is recommended to assess for arterial dissection, atherosclerotic plaque, and intracranial stenosis. 2, 4
• Cardiac assessment must include a 12‑lead ECG and at least 14 days of continuous cardiac rhythm monitoring to uncover paroxysmal atrial fibrillation, a key cardioembolic source even in young adults. 3

Cardiac Evaluation for Paradoxical Embolism

• Transthoracic echocardiography with agitated‑saline (“bubble”) study should be performed in all patients < 45 years when the initial work‑up is unrevealing, to screen for patent foramen ovale (PFO) and right‑to‑left shunting. 2, 3
• Transesophageal echocardiography is indicated when the TTE is inconclusive or when structural cardiac pathology is strongly suspected; TEE alters management in approximately 16–17 % of young stroke/TIA patients by identifying candidates for anticoagulation or PFO closure. 3
• Transcranial Doppler ultrasound with bubble study provides a non‑invasive alternative, demonstrating 96 % sensitivity and 92 % specificity for detecting right‑to‑left shunt compared with TEE. 3

Hypercoagulable State Evaluation

• Selected thrombophilia testing (protein C, protein S, antithrombin III, Factor V Leiden, and prothrombin G20210A) is appropriate in young patients lacking conventional cardiovascular risk factors and with clinical clues to hypercoagulability. 3
• Because inherited thrombophilia results rarely modify acute treatment decisions, testing should not postpone initiation of antiplatelet therapy. 3

Autoimmune and Inflammatory Vasculitis Screening

• In patients with systemic inflammatory signs or without traditional risk factors, an autoimmune panel—including ESR, CRP, ANA, anti‑double‑stranded DNA, complement C3/C4, and, when vasculitis is suspected, ANCA—should be obtained. 3, 1

Vascular Imaging for Hemorrhagic and Venous Pathology

• For patients < 45 years presenting with lobar or deep/posterior‑fossa hemorrhage without a history of hypertension, head CTA with venography is advised to exclude cerebral arteriovenous malformations and cerebral venous thrombosis. 5
• Vertebrobasilar imaging is essential because symptomatic vertebrobasilar stenosis identifies individuals at high risk for recurrent stroke. 3

Toxicology and Substance Use

• Urine toxicology screening for cocaine and other illicit drugs should be performed at presentation; cocaine use within the preceding 24 hours raises the risk of stroke in young adults by more than six‑fold. 3

Genetic and Monogenic Causes

• Systematic application of diagnostic algorithms reveals monogenic etiologies in roughly 7 % of young stroke/TIA patients, supporting consideration of targeted genetic testing when standard investigations are nondiagnostic. 3

Transient Ischemic Attack Management Guidelines

Risk Stratification and Diagnosis

• The American Heart Association recommends calculating and documenting the ABCD2 score explicitly, which includes factors such as age, blood pressure, clinical features, duration of symptoms, and diabetes, to determine the risk of stroke in patients with transient ischemic attack (TIA) 6, 7
• High-risk patients with an ABCD2 score of 4 or higher face an 8% risk of stroke at 2 days, compared to 1% in low-risk patients 6
• Documenting the time from symptom onset to presentation is critical for treatment decisions, as it helps determine the eligibility for certain treatments 6, 7
• The American Stroke Association suggests specifying the vascular territory affected by the TIA, whether it is the anterior circulation (carotid territory) or posterior circulation (vertebrobasilar territory), to guide further management 8

Diagnostic Workup and Etiology Determination

• The American College of Cardiology recommends completing brain imaging, such as CT or MRI, to exclude hemorrhage and identify acute infarction in patients with TIA 9, 6, 7
• Vascular imaging, including carotid Doppler and CTA or MRA, should be performed to evaluate the extracranial and intracranial vessels 6, 7
• Cardiac evaluation, including ECG and rhythm monitoring, should be performed to identify potential cardioembolic sources 9, 7
• Laboratory results, including CBC, electrolytes, creatinine, fasting glucose, HbA1c, lipid profile, and coagulation studies, should be documented to guide further management 9, 7
• The American Heart Association recommends documenting the suspected mechanism of the TIA, including large artery atherosclerosis, cardioembolic, small vessel disease, or cryptogenic 10, 7

Treatment and Management

• The American College of Cardiology recommends initiating antiplatelet therapy, including dual antiplatelet therapy with aspirin and clopidogrel for 21 days, in high-risk patients with non-cardioembolic TIA 6, 7
• Anticoagulation therapy should be initiated in patients with cardioembolic TIA, with a target INR of 2.0-3.0 10, 7
• Statin therapy should be initiated in all patients with TIA, regardless of baseline cholesterol level 6
• Blood pressure management should be initiated, with a target blood pressure of less than 130/80 mmHg, typically waiting 7-14 days before starting antihypertensives unless severely elevated 11, 6

Disposition and Follow-up

• High-risk patients with an ABCD2 score of 4 or higher should be admitted to a stroke unit for continuous monitoring 6, 7
• Low-risk patients with an ABCD2 score of less than 4 may be managed as outpatients with neurology follow-up within 7-10 days 7
• Urgent surgical evaluation should be considered in patients with symptomatic carotid stenosis greater than 70%, with documentation of vascular surgery consultation for endarterectomy within 2 weeks 10, 6, 7
• Neurology follow-up should be arranged within 2 weeks, with clear medication instructions and documentation of medication reconciliation 6, 7